[Recurrent hypersomnia].

H Suzuki

Home/Archive/PubMed

PubMed · 9503836

[Recurrent hypersomnia].

H Suzuki

View original source ↗Export metadata ↓

Abstract

The recurrent hypersomnia is a rare disorder and diagnosed by recurrent episodes of hypersomnia more than 18 hours a day lasting from several days to several weeks. The Kleine-Levin syndrome is a subtype of the recurrent hypersomnia and characterized by excessive eating or hypersexuality. I review the clinical features of recurrent hypersomnia comparing with our own two cases. The slight consciousness disturbance is seemed to cause the hypersomnic state. Several neurophysiological findings also support this hypothesis. Generally, the prognosis of this disorder is good. The psychophysical factor is seemed as a major factor to induce this disorder, therefore to reduce this factor is one of the most important treatment and the lithium carbonate is also useful as a pharmacotherapy. The mechanism of this disorder is still unknown.

Explore related subjects

Antidepressive Agents Antimanic Agents Diagnosis, Differential Humans Kleine-Levin Syndrome Lithium Carbonate Prognosis English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H Suzuki. 1998. [Recurrent hypersomnia].. https://pubmed.ncbi.nlm.nih.gov/9503836/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

[Antidepressants and somatic disease].

Depression is the most frequent psychiatric disease associated with chronic somatic disorders. Diagnosis, however, is frequently difficult to make, due on one hand to the presence of symptoms that depression and chronic somatic disorders have in common, and on the other hand to the assumption shared by the physician and its patient that depression is a normal reaction to a somatic illness. Accurate diagnosis is nevertheless necessary in order to initiate the appropriate treatment. A review of pharmacological treatments of depression related to frequent chronic somatic disorders is presented.

Antidepressive Agents↗

PubMed1999

Sleep deprivation in depression: what do we know, where do we go?

Manipulations of the sleep-wake cycle, whether of duration (total or partial sleep deprivation [SD]) or timing (partial SD, phase advance), have profound and rapid effects on depressed mood in 60% of all diagnostic subgroups of affective disorders. Relapse after recovery sleep is less when patients are receiving medication; it may be prevented by co-administration of lithium, pindolol, serotonergic antidepressants, bright light, or a subsequent phase advance procedure. Diurnal and day-to-day mood variability predict both short-term response to SD and long-term response to antidepressant drug treatment. These mood patterns can be understood in terms of a "two-process model of mood regulation" based on the model well established for sleep regulation: the interaction of circadian and homeostatic processes. The therapeutic effect of SD is postulated to be linked to changes in disturbed circadian- and sleep-wake-dependent phase relationships and concomitant increase of slow-wave-sleep pressure; additionally, SD-induced sleepiness may counteract the hyperarousal state in depression. This model has the advantage of providing a comprehensive theoretical framework and stringent protocols ("constant routine," "forced desynchrony") to dissect out specific disturbances. Many aspects tie in with current serotonergic receptor hypotheses of SD action. A treatment inducing euthymia in severely depressed patients within hours is an important therapeutic option that has come of age for clinical use.

Antidepressive Agents↗

PubMed1999

Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.

Many psychotropic drugs interfere with the reuptake of dopamine, norepinephrine, and serotonin. Transport capacity is regulated by kinase-linked pathways, particularly those involving protein kinase C (PKC), resulting in transporter phosphorylation and sequestration. Phosphorylation and sequestration of the serotonin transporter (SERT) were substantially impacted by ligand occupancy. Ligands that can permeate the transporter, such as serotonin or the amphetamines, prevented PKC-dependent SERT phosphorylation. Nontransported SERT antagonists such as cocaine and antidepressants were permissive for SERT phosphorylation but blocked serotonin effects. PKC-dependent SERT sequestration was also blocked by serotonin. These findings reveal activity-dependent modulation of neurotransmitter reuptake and identify previously unknown consequences of amphetamine, cocaine, and antidepressant action.

Antidepressive Agents↗